tldrdaily.news logo
Tag

Car T Therapies

All articles tagged with #car t therapies

business1 year ago

Roche Acquires Poseida for $1.5B, Boosting CAR-T Therapy Access

Roche has agreed to acquire Poseida Therapeutics for $1.5 billion, integrating Poseida's CAR-T therapies and manufacturing capabilities into its Pharmaceuticals Division. The deal includes a tender offer for Poseida's shares at $9 each, with potential milestone payments. The acquisition, approved by both companies' boards, is expected to close in Q1 2025, enhancing Roche's cell therapy development in oncology, immunology, and neurology.

via Yahoo Finance|
#acquisition#business#car-t-therapies
business1 year ago

Roche Acquires Poseida Therapeutics in $1.5B Deal to Expand CAR-T Access

Poseida Therapeutics, a clinical-stage biopharmaceutical company, has agreed to be acquired by Roche Holdings for up to $1.5 billion. Poseida stockholders will receive $9.00 per share in cash at closing, plus a contingent value right for up to an additional $4.00 per share. The acquisition will enhance Roche's capabilities in allogeneic cell therapy, particularly in CAR-T programs for cancer and autoimmune diseases. The transaction is expected to close in the first quarter of 2025, pending regulatory approvals and other conditions.

via PR Newswire|
#acquisition#biopharmaceuticals#business
health2 years ago

FDA Warns of Increased Cancer Risk from CAR-T Therapies

The FDA has issued a warning that CAR-T therapies, which involve genetically engineering T cells to target and kill cancer cells, may themselves cause secondary blood cancers. The agency has required companies to add a boxed warning to these specialized cancer treatments, despite noting that the benefits still outweigh the risks. While the therapy has been used by at least 27,000 patients since 2017, reports of about 25 cases of secondary cancers have raised concerns, although further investigation is needed to establish a definite link.

via The New York Times|
#boxed-warning#cancer-risk#car-t-therapies
healthcare2 years ago

"FDA Requires Boxed Warnings for Secondary Cancer in CAR-T Therapies"

The FDA has instructed several pharmaceutical companies to include boxed warnings on the labels of six CAR-T therapies, cautioning about the risks of secondary cancer. This move follows a safety review initiated by the agency in November, which has sparked discussions within the CAR-T space. While secondary cancers are a known but uncommon risk of many anti-cancer treatments, most experts believe they remain rare and represent a relatively small risk factor for an otherwise effective drug class.

via Endpoints News|
#boxed-warnings#cancer#car-t-therapies